DDrare: Database of Drug Development for Rare Diseases

Searched query = "Myelomeningocele", "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Atosiban; Botulinum A toxin; Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique; Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique; Device: Minimally invasive fetoscopic repair of MMC; Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics); MMC; MONITOR; Placental Mesenchymal Stem Cells; Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix; Procedure: Fetal surgery for MMC repair; Procedure: endoscopic repair of myelomeningocele before 26 SA; SA; Terbutaline; Uterine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04652908 (ClinicalTrials.gov)	February 2021	25/11/2020	Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial	Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele	Myelomeningocele	Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix	Diana Lee Farmer	California Institute for Regenerative Medicine (CIRM)	Not yet recruiting	19 Weeks	25 Weeks	All	35	Phase 1;Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04652908
(ClinicalTrials.gov)

February 2021

25/11/2020

Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial

Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele

Myelomeningocele

Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix

Diana Lee Farmer

California Institute for Regenerative Medicine (CIRM)

Not yet recruiting

19 Weeks

25 Weeks

All

Phase 1;Phase 2

NULL